✦ LIBER ✦

Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease

✍ Scribed by Jennifer Williams; Peter C. Lucas; Kent A. Griffith; Milheon Choi; Sarah Fogoros; Yuan Yuan Hu; J. Rebecca Liu

Book ID: 113959651
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 446 KB
Volume: 96
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2004.10.026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Class III β-tubulin expression in advanc

Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance

✍ Thea Eline Hetland; Ellen Hellesylt; Vivi Ann Flørenes; Claes Tropé; Ben Davidso 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 533 KB

Bcl-XL and Bcl-2 Expression in Bilharzia

Bcl-XL and Bcl-2 Expression in Bilharzial Squamous Cell Carcinoma of the Urinary Bladder: Which Protein Is Prognostic?

✍ Diaa A. Hameed; Ahmad M. Abdel Raheem; Eman Mosad; Hisham M. Hammouda; Nermen A. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 488 KB

Bcl-xL is heterogeneously expressed by a

Bcl-xL is heterogeneously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression

✍ Pallis, M; Zhu, Y-M; Russell, N H 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 236 KB

Retinamide-Induced Apoptosis in Glioblas

Retinamide-Induced Apoptosis in Glioblastomas is Associated with Down-Regulation of Bcl-xL and Bcl-2 Proteins

✍ Richard A. Lytle; Zhihong Jiang; Xiao Zheng; Ryuji Higashikubo; Keith M. Rich 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 363 KB

Loss of SOCS3 expression is associated w

Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma

✍ Mingzhen Ying; Dawei Li; Linjun Yang; Mei Wang; Ning Wang; Ying Chen; Miaoxia He 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 600 KB

The Bcl-xL inhibitor of apoptosis is pre

The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma

✍ Natasa Vasiljević; Kristin Andersson; Kaj Bjelkenkrantz; Christer Kjellström; He 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 281 KB

## Abstract Keratoacanthoma (KA) is difficult to histologically distinguish from squamous cell carcinoma (SCC). Therefore, although KA is a benign self‐resolving skin lesion, KA is commonly treated as SCC. Biomarkers to distinguish KA and SCC would thus be desirable. In search for specific markers,